Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post by Rami Manochakian, adding:
“Press release: FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant and clinically meaningful.” Combos may be in, but informed and shared decision-making stays key. Excited to review full data.”
Quoting Rami Manochakian‘s post:
“Hot Off the Press BigNews
Press Release by AstraZeneca
FLAURA2 trial of Osimertinib + Chemotherapy vs Osimertinib in 1st line Tx for patients with EGFR+ advanced Lung Cancer (NSCLC) shows:
Statistically Significant and Clinically Meaningful Improvement in Overall Survival.”
More posts featuring Eric Singhi.
